1. Scrip
  2. >>Therapy Areas

Anthos Takes On Pharma Giants In Factor XI Anticoagulation Space

Start-Up Was First To Start A Phase III Trial

 
• By Mandy Jackson

CEO John Glasspool spoke with Scrip about why Anthos believes it has a good shot against big competitors in a market that is expected to generate blockbuster sales across multiple products.

3d illustration red blood cells circulating in the blood vessels
Anthos's first Phase III trial aims to prevent blood clots in cancer patients • Source: Shutterstock

Anthos Therapeutics Inc. is the first biopharmaceutical firm to take a Factor XI inhibitor into a Phase III clinical trial, putting the company ahead of at least two big pharma competitors hoping to bring novel anticoagulants to market with the potential to prevent blood clots without increasing bleeding risk. CEO John Glasspool told Scrip that Anthos believes its abelacimab will also be the first Factor XI product to market.

Cambridge, MA-based Anthos launched in 2019 with $250m from Blackstone Life Sciences and with a license from Novartis AG for abelacimab, which targets Factors XI and XIa. (Also see "Finance Watch: VC Mega-Deals Launch Biopharma Firms With New Takes On CV, Genetic Diseases" - Scrip, 5 March, 2019.) Glasspool previously was executive vice president and head of corporate strategy and customer operations at Baxalta Incorporated

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Cardiovascular

Merck & Co. CMO Eliav Barr Assures On Pipeline As Keytruda LOE Looms Large

 
• By Jessica Merrill

Chief medical officer Eliav Barr, responsible for overseeing clinical development, talked to Scrip in an interview at Merck’s headquarters about the company’s pipeline diversification.

CNS, Cardiometabolics A Bright Spot In Recent Chinese VC/PE Fundings

 
• By Dexter Jie Yan

Over the past few months, Chinese developers of CNS and cardiometabolic therapies have attracted the interest of domestic investors, amid generally modest funding activity.

US FDA Expands Label For BMS’s Camzyos Days After Phase III Stumble

 
• By Alaric DeArment

The agency loosened requirements for echocardiograms and removed contraindications for a number of commonly used drugs.

Camzyos nHCM Failure Could Open Door To Threat From Cytokinetics’ Aficamten

 
• By Alaric DeArment

BMS’s Phase III ODYSSEY-HCM study did not show statistical significance for either of its two primary endpoints.

More from Therapy Areas

AstraZeneca COPD Drug Breztri Breezes Through Asthma Trials

 
• By Kevin Grogan

The triple therapy improves lung function in the Phase III KALOS and LOGOS studies

Zepbound Grows, But CVS/Novo Nordisk Deal For Wegovy Casts Shadow

 
• By Alaric DeArment

Lilly executives told the company’s Q1 call they were not surprised at the Wegovy deal, but some analysts said it could cut into prescription growth for Zepbound.

GSK Talks Up Nucala COPD Hospitalization Data In Challenge To Dupixent

 
• By Kevin Grogan

As the PDUFA date for the UK major’s IL-5 inhibitor draws close.